Visuel - Landing page

 Our publications about Cancer

🔎 Association of adherence to endocrine therapy among patients with breast cancer an potential drug-drug interactions (JAMA Network, 2022).

🔎 Impact of potential drug-drug interactions (PDDI) on adherence to endocrine therapy (ET) among patients with breast cancer (BC) in the Health Improvement Network (THIN) (Annals of Oncology, 2022).

🔎 An evaluation of a national mass media campaign to raise public awareness of possible lung cancer symptoms in England in 2016 and 2017 (British Journal of Cancer, 2022).

🔎 A prospective evaluation of the fourth national Be Clear on Cancer 'Blood in Pee' campaign in England (European Journal of Cancer Care, 2022).

🔎 And more...

About THIN®️

THIN®️ (The Health Improvement Network) is a large European database of anonymized Electronic Health Records collected at the physicians’ level, owned by the Cegedim group.

THIN®️ anonymized longitudinal patient data currently covers large populations of over 69 million patients across several European countries (France, the UK, Spain, Italy Belgium and Romania). 

The THIN®️ database is referenced by healthcare authorities in France and in the UK and approx.  2,000 scientific papers have been published. 

Cegedim Health Data provides anonymized Real-World Data and Evidence (RWD-E) platforms and advanced studies to drive cutting-edge improvements in patient outcomes in the interests of public health.

Ask for RWD expertise or datasets